Stryker (SYK) Draws Fresh Valuation Focus, Is A 15% Upside Enough?

Why a valuation comparison is drawing attention to Stryker stock

A recent Zacks comparison between Stryker (SYK) and Prestige Consumer Healthcare has refocused attention on Stryker stock, after Zacks assigned Stryker a Rank #3 Hold and a Value grade of C.

Stryker’s share price has recently moved higher, with a 1-day share price return of 2.66% and a 90-day share price return of 10.43%. This is even though the year-to-date share price return is down 5.02% and the 1-year total shareholder return is down 14.65%, while the 3-year and 5-year total shareholder returns of 19.71% and 25.90% point to a more resilient longer term record.

Compare Stryker’s recent moves with a curated group of companies that also combine established operations with valuation appeal by scanning our 45 high quality undervalued stocks.

For Stryker, that recent upward move sits between two explanations. Either investors are re-rating a solid medical technology business or sentiment is simply swinging back after a weaker run. The valuation metrics help show which story fits.

Most Popular Narrative: 14.5% Undervalued

The most followed narrative currently places Stryker’s fair value at $386.80, above the last close of $330.69. This frames the recent share price recovery in a different light.

The ongoing industry shift to outpatient and minimally invasive procedures, where Stryker is a leading supplier of ASC infrastructure and advanced surgical solutions, positions the company to benefit from increased procedure volumes and deeper customer penetration, bolstering both revenue and operating leverage.

Read the complete narrative.

Want to see what underpins that premium fair value for Stryker? The narrative leans heavily on procedure growth, margin expansion and a richer earnings multiple. The interesting part is how these three levers interact over the next few years.

Result: Fair Value of $386.80 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Stryker narrative still faces pressure from possible regulatory delays in Europe and ongoing supply chain disruptions that could weigh on revenue and margins.

Find out about the key risks to this Stryker narrative.

Next Steps

Given the mix of optimism and concern around Stryker, it helps to review the same information yourself and decide quickly where you stand. To weigh those upsides against the open questions, take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Stryker?

If Stryker has sharpened your focus on quality, do not stop here. You can broaden your watchlist with fresh ideas that could suit very different goals.

• Target potential mispricing opportunities by scanning companies that combine quality fundamentals with valuation appeal through the 45 high quality undervalued stocks.
• Prioritise resilience and capital protection by reviewing a 75 resilient stocks with low risk scores that filters for stocks with sturdier risk profiles.
• Hunt for future leaders before the crowd catches on by checking a 19 high quality undiscovered gems with strong underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com